...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine Research >The Effect of Tofogliflozin Treatment on Postprandial Glucose and Lipid Metabolism in Japanese Men With Type 2 Diabetes: A Pilot Study
【24h】

The Effect of Tofogliflozin Treatment on Postprandial Glucose and Lipid Metabolism in Japanese Men With Type 2 Diabetes: A Pilot Study

机译：托福列净治疗对日本2型糖尿病男性餐后葡萄糖和脂质代谢的影响：一项初步研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Postprandial hyperglycemia and hyperlipidemia are highly related to the development of atherosclerosis. Sodium/glucose cotransporter-2 (SGLT2) inhibitors have attracted attention as a new class of anti-diabetic agents for the treatment of type 2 diabetes. We investigated the effect of tofogliflozin on postprandial glucose and lipid metabolism in Japanese male patients with type 2 diabetes.Methods: Ten Japanese men with type 2 diabetes (average age 66.3 years) were orally administered tofogliflozin (20 mg per day) for 8 weeks followed by a subsequent 8 weeks of washout of the agent. At 0, 8 and 16 weeks, postprandial metabolic parameters were measured at 0, 60 and 120 min after cookie ingestion.Results: There were significant reductions in body weight and body mass index at 8 weeks. There was a reduction in HbA1c at 8 weeks, which returned to pretreatment levels at 16 weeks. Serum insulin levels did not change during the entire study period under either fasting or postprandial state. The area under the curve of plasma glucagon significantly increased at 8 weeks. There were no changes in lipid and lipoprotein levels either in fasting or postprandial state except for tendency toward reduction in postprandial triglycerides at 8 weeks and increase in HDL-C at 16 weeks.Conclusions: Tofogliflozin treatment causes an improvement of postprandial glucose metabolism but not considerable postprandial lipid metabolism.J Clin Med Res. 2017;9(5):403-409doi: https://doi.org/10.14740/jocmr2806w
机译：背景：餐后高血糖和高血脂与动脉粥样硬化的发展高度相关。钠/葡萄糖共转运蛋白2（SGLT2）抑制剂作为治疗2型糖尿病的新型抗糖尿病药引起了人们的关注。我们研究了Tofogliflozin对日本2型糖尿病男性患者餐后葡萄糖和脂质代谢的影响。方法：对10名日本2型糖尿病男性患者（平均年龄66.3岁）口服Tofogliflozin（每天20 mg），持续8周。通过随后的8周药剂清洗。在第0、8和16周，在饼干摄入后0、60和120分钟测量饭后代谢参数。结果：在8周时，体重和体重指数显着降低。 8周时HbA1c降低，并在16周时恢复到治疗前水平。在空腹或餐后状态下，整个研究期间血清胰岛素水平均未改变。血浆胰高血糖素曲线下的面积在8周时显着增加。禁食或餐后状态的脂质和脂蛋白水平没有变化，除了餐后甘油三酯在第8周降低和HDL-C在第16周升高的趋势外。结论：Tofogliflozin治疗可改善餐后葡萄糖代谢，但影响不大。餐后脂质代谢。《临床医学杂志》。 2017; 9（5）：403-409doi：https://doi.org/10.14740/jocmr2806w

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号